The two-year point where results go in opposite directions

Both microfracture and ChondroFiller injection can produce meaningful symptom relief in the first year — reduced pain, improved function, a genuine sense that something has changed. For patients trying to choose between them, that early similarity is precisely what makes the comparison misleading.

The results begin to separate at around two years and diverge further through years three to five. Functional scores after microfracture reliably decline beyond this point, with a pooled dataset recording a 62% treatment failure rate at a median of four years. ChondroFiller injection outcomes, by contrast, hold or continue to improve at three-year follow-up.

The reason is biological, not technical. It has little to do with surgical skill or the precision of the procedure and everything to do with the type of repair tissue each approach generates — and how that tissue responds once sustained joint loading sets in. Understanding that difference is what allows a realistic assessment of long-term expectations rather than a choice based on early signal alone.

The sections below work through each mechanism in turn, then examine what the clinical evidence shows at the points where the gap becomes clinically significant.

What microfracture produces inside the joint

Microfracture works by deliberately breaching the subchondral bone plate — the dense layer of bone directly beneath the cartilage surface — with a surgical pick or awl. The perforations release a blood-and-marrow clot into the defect, carrying mesenchymal stem cells that migrate into the space and begin to differentiate. The critical issue is what they differentiate into: not hyaline chondrocytes, but fibrochondrocytes, which produce fibrocartilage.

Fibrocartilage is dominated by Type I collagen — the same structural protein found in scar tissue — and is notably poor in glycosaminoglycans, the molecules that allow native cartilage to bind water and distribute compressive load. A PMC systematic review confirms this biochemical distinction explicitly: the resulting tissue fills the void and provides adequate short-term function, but it lacks the mechanical resilience of a true Type II collagen matrix. Under the cumulative loading of daily movement, it breaks down progressively — the structural explanation for the functional decline that Mithoefer et al. identified as a consistent finding after the two-year mark.

The bone perforations carry an additional consequence that is less often discussed: pathological subchondral changes — including cyst formation and intralesional osteophytes — can develop at the treated sites. These changes may limit or complicate any subsequent cartilage repair procedure, narrowing future options in ways that are not always apparent at the time of surgery.

Historically, the technique was best suited to focal defects smaller than 2–4 cm² in younger, active patients, and it remains widely performed — approximately 78,000 procedures annually in the United States. Its use has nonetheless declined as longer follow-up data have confirmed that fibrocartilage breakdown is not an occasional complication but a predictable biological outcome. The four-year failure estimate noted in the opening section reflects a pooled, heterogeneous case series and should be read as an indicator of the broader trend rather than a fixed universal rate.

How ChondroFiller injection works differently

The ChondroFiller injection takes an entirely different approach — and leaves the subchondral bone untouched.

ChondroFiller® liquid is an acellular injectable scaffold composed of murine-derived Type I/III collagen, CE-marked as a Class III medical device. It is delivered as a single outpatient treatment under ultrasound guidance — no arthroscopy, no theatre, no bone drilling. Once placed within the defect, the scaffold gels in situ within minutes, conforming to the space and providing an immediate structural matrix for repair.

Being acellular, the scaffold introduces no cells of its own. Instead it acts as a chemotactic signal, drawing the patient's endogenous progenitor cells into the defect site. Over the following six to twelve months those cells migrate into the scaffold and differentiate, depositing a hyaline-like matrix — one richer in Type II collagen and glycosaminoglycans than the fibrocartilage that marrow stimulation produces. That biochemical profile brings the repair tissue closer in composition to native articular cartilage and better positioned to sustain repeated joint loading over time. This process is sometimes described as matrix-induced chondrogenesis: the scaffold does not grow new cartilage itself, but creates the structural and biological conditions for the body to do so.

The structural contrast with microfracture is direct. Because no perforation of the bone plate is required, the subchondral architecture remains fully intact — none of the cyst formation or osteophyte development described in the previous section, and no structural changes that would narrow future treatment options.

Single-agent injection is documented for focal defects up to approximately 3 cm²; combination protocols extend coverage to around 6 cm² for larger lesions.

Why cumulative loading separates the outcomes after year two

Loading is the decisive variable — not the early months, when both repairs are shielded from peak demand, but the sustained compression that accumulates over years of everyday movement.

In the first 12 to 18 months, fibrocartilage is adequate to the task. It fills the defect, provides cushioning, and reduces symptoms. The ChondroFiller scaffold is simultaneously maturing: progenitor cells are migrating in and depositing new matrix, but consolidation is incomplete. At this stage, functional scores from both approaches are broadly comparable.

The separation begins as cumulative loading compounds beyond year two. Fibrocartilage — Type I collagen-dominant and poor in proteoglycans, as described in the previous section — cannot redistribute compressive force efficiently. Without the glycosaminoglycans that give native cartilage its water-binding resilience, the fibres fatigue and the matrix thins under repeated stress. Hyaline-like tissue behaves differently: its Type II collagen architecture and glycosaminoglycan density allow it to absorb and release water under load — a mechanism that consolidates the repair over time rather than degrading it. The two outcome curves move in opposite directions for this biological reason.

Bone perforation introduces a further compounding effect over the same period. The subchondral changes that can follow microfracture alter the mechanical environment beneath the repair in ways that may accelerate surface breakdown independently of repair tissue quality — compressing the patient's future options in the process.

Analogous evidence for the tissue-type principle comes from the SUMMIT trial, which compared MACI — a different scaffold entirely, not ChondroFiller — against microfracture in defects of 3 cm² or larger. MACI produced meaningfully better KOOS pain and function scores at both two and five years, reinforcing that hyaline-like regeneration sustains loading where fibrocartilage does not.

The gap is not abrupt. It widens gradually across years two to five, which is why outcome data collected at only 12 or 18 months can obscure the trajectory that longer follow-up reveals.

What the evidence actually shows — and where the gaps remain

The evidence behind these two approaches differs in provenance as much as in outcome — and that distinction matters for how the numbers should be read.

For microfracture, the evidence base is independent and well-established. A systematic review by Mithoefer et al. confirmed excellent short-term efficacy at two years, followed by reliable functional decline — a pattern replicated across multiple studies. A pooled dataset recorded 62% of microfracture repairs classified as treatment failures at a median four-year follow-up (range 1–18 years); the dataset includes surgically heterogeneous cases, so that figure is best read as a signal of limited durability rather than a precise failure-rate benchmark.

The ChondroFiller injection evidence is clinically meaningful but derives primarily from manufacturer-associated studies, and independent large-scale RCTs directly comparing ChondroFiller injection with microfracture at five or more years are not yet available. The strongest current data comes from the prospective post-market clinical follow-up study by Jerosch et al., which recorded a mean IKDC improvement of 32.4 points — sustained and slightly increased at three-year follow-up, with patients reaching a mean functional score of 80. MOCART imaging scores of 81.6 to 84.3 in European cohorts confirm greater than 80% structural defect filling and good peripheral integration. Both this result and earlier ChondroFiller knee data consistently exceed the established minimum clinically important difference threshold of 16.7 IKDC points — a benchmark that allows patients and referring clinicians to calibrate what functional change means in practice, not just statistically.

The SUMMIT trial result discussed in the previous section — MACI outperforming microfracture at two and five years — supports the tissue-type principle, but MACI is a distinct two-stage procedure using cultured autologous cells. It is not a ChondroFiller study and should not be read as proxy evidence for it.

The three-year Jerosch PMCF data represents the best available comparative window for the injection. Longer-term registry data is still maturing, and that limitation is worth holding alongside the encouraging early trajectory.

Which patients are suited to each approach — and what to discuss at assessment

Deciding between microfracture and a ChondroFiller injection depends not only on the evidence reviewed above, but on individual defect characteristics, loading history, and prior treatment — factors that only a specialist assessment can weigh together.

Microfracture retains a defined historical role for focal defects smaller than approximately 2 cm² in younger, active patients who have not previously undergone marrow-stimulation surgery. For that specific profile it can remain a reasonable option. Patients considering it should understand its functional ceiling and the possibility of subchondral bone changes that may complicate any subsequent repair if the fibrocartilage eventually breaks down.

ChondroFiller injection suits a broader candidacy range. No upper age limit is specified, and single-agent use is documented for defects up to 3 cm², with combination protocols extending coverage further. Because the subchondral bone is left entirely intact, future repair options are not foreclosed in the way they can be after marrow stimulation.

Patients who have already had microfracture face a more complex picture. Prior marrow stimulation does not rule out further repair, but the subchondral changes it may have introduced alter the planning considerably — specialist review of current imaging is necessary before any next step is decided.

Neither technique is appropriate for advanced, diffuse osteoarthritis. A focal defect, confirmed by MRI and clinical grading, is a prerequisite for either pathway.

Key factors to bring to a specialist consultation: defect size and ICRS grade, defect location, cumulative loading history, and whether prior marrow stimulation has altered the subchondral architecture. Establishing these clearly is what allows a realistic, individual repair plan to be made.